Navigation Links
Historic trial for tuberculosis launched together by leading drug companies

Two leading pharmaceutical companies, The Global Alliance for TB Drug Development (TB Alliance) and Bayer Healthcare have announced a partnership to coordinate the study to uncover the potential of an existing antibiotic, //Moxifloxacin, to shorten the standard 6-month treatment of tuberculosis (TB).

Mycobacterium tuberculosis infects one-third of the world's population, resulting in nine million new cases of active TB and two million deaths each year. Current TB therapy involves the use of four drugs discovered forty or more years ago and must be given for six to eight months, under the direct observation of a healthcare provider. A shorter protocol is believed to reduce side effects, improve patient adherence to therapy, and save lives.

The trial would examine the effects of substituting moxifloxacin for one of the standard TB drugs (ethambutol or isoniazid). It is hypothesized that the new drug would eliminate TB infection faster than the existing treatment. In vivo preclinical studies have already shown that the drug significantly reduces treatment time by two months. If the trials are successful, the partnership aims to register moxifloxacin for a TB indication and is committed to making it affordable and accessible in developing countries where there is an utmost needed. The trials would take place in Brazil, Canada, South Africa, Spain, Tanzania, Uganda, the United States and Zambia. Bayer will donate moxifloxacin for each trial site and will cover the costs of regulatory filings. The TB Alliance will coordinate and help cover the costs of the trials. "We are witnessing an historic moment in global health," said Dr. Maria C. Freire, President and CEO of the TB Alliance. "Today, we stand with Bayer, embarking on a major clinical trial program to see if this excellent antibiotic can shorten TB treatment by 2-3 months, which would significantly improve therapy."

"Bayer is committed to working with the TB Alliance to develop a sho rter TB therapy and we are proud to make a tangible contribution and to participate in the movement to achieve the Millennium Development Goal to reverse tuberculosis as a major global health pandemic by 2015." said Dr. Wolfgang Plischke, head of the pharmaceuticals division of Bayer HealthCare.

"This is an important step toward developing a new generation of TB treatments. We urgently need to improve upon current TB drugs, which were developed more than 40 years ago," said Dr. Helene Gayle, Director, HIV, TB and Reproductive Health at the Bill & Melinda Gates Foundation. "By innovating with an existing product, Bayer and the TB Alliance could make an improved TB treatment available much faster than would otherwise be possible."
'"/>




Related medicine news :

1. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
2. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
3. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
4. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
5. Historic Increase In Incidence Of Sexually Transmitted Diseases In Scotland
6. Black-Owned Hospital Receives Historical Commemorative Marker
7. Man against HIV – new vaccine ready for human trials
8. Male contraceptive in trial
9. How do patients benefit of clinical trials
10. Glenmark’s new molecule to go through trial
11. Clinical trials need to be more frank
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: